Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...
Figure 1. 4Q25 ResultsSources: Company reports, Wedbush estimates, FactSet consensus4Q results were ahead of expectations. Gross bookings of $43.0B (+15.9% Y/Y) in the quarter were ahead of consensus of $42.0B (+13.1% Y/Y) by ~3% and exceeded the high end of management's guidance range (+11% to +13
HBT Financial, Inc. Ranked #1 on Forbes’ 2026 America’s Best Banks List BLOOMINGTON, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- HBT Financial, Inc. (NASDAQ: HBT) (“HBT Financial”), the parent company of Heartland Bank and Trust Company (“Heartland Bank”), today announced it has been ranked #1 on Forbes’ 17th annual list of America’s Best Banks. The prestigious ranking, published February 4, identifies the 100 strongest banks in the nation based on an objective analysis of 11 key metrics. The 200 largest publicly traded banks and thrifts by asset size were analyzed. Forbes evaluated banks ba...
A director at Monolithic Power Systems Inc sold/sold after exercising options 33,000 shares at 1,171.826USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...
Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 4Q results and provided a healthy outlook for 1Q. Nights and Experiences booked growth in 4Q of +15.9% Y/Y was ~560bps above Street estimates. Revenue and adj. EBITDA were ahead of expectations
Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regen...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIR...
Monolithic Power Systems Announces CFO Transition SCHAFFHAUSEN, Switzerland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Monolithic Power Systems, Inc. (“MPS”) (Nasdaq: MPWR), a fabless global company that provides high-performance, semiconductor-based power electronics solutions, today announced that Bernie Blegen will retire from his position as Executive Vice President and CFO effective following the issuance of MPS’s 2025 annual report on Form 10-K. Mr. Blegen will remain with MPS after his retirement to ensure a smooth transition with his eventual successor. “Bernie started with MPS in 2011 a...
Monolithic Power Systems Announces Results for the Fourth Quarter and Year Ended December 31, 2025 and an Increase in Quarterly Cash Dividend SCHAFFHAUSEN, Switzerland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Monolithic Power Systems, Inc. (“MPS”) (Nasdaq: MPWR), a fabless global company that provides high-performance, semiconductor-based power electronics solutions, today announced financial results for the quarter and year ended December 31, 2025. MPS also announced that its Board of Directors has approved an increase in the quarterly cash dividend from $1.56 per share to $2.00 per share. The...
Monolithic Power Systems Provides Earnings Commentary for the Quarter and Year Ended December 31, 2025 SCHAFFHAUSEN, Switzerland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- MPS reported its results after market close on February 5, 2026 and will host a question-and-answer webinar at 2:00 p.m. PT / 5:00 p.m. ET. The webinar can be accessed at . 2025 Financial Summary (Unaudited) GAAP 20252024 YoY ChangeYoY Change (%)Revenue ($k)$ 2,790,459$ 2,207,100 $ 583,35926.4%Gross Margin55.2%55.3% (0.1) pts(0.2)%Opex ($k)$ 811,105$ 681,512 $ 129,59319.0%Operating Margin26.1%24.4% 1.7 pts7.0%Net income ($k)...
O’Reilly Automotive, Inc. Reports Fourth Quarter and Full-Year 2025 Results Fourth quarter comparable store sales growth of 5.6%, full-year increase of 4.7%13% increase in fourth quarter diluted earnings per share to $0.71, full-year increase of 10% to $2.97$2.8 billion net cash provided by operating activities in 2025 SPRINGFIELD, Mo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- O’Reilly Automotive, Inc. (the “Company” or “O’Reilly”) (Nasdaq: ORLY), a leading retailer in the automotive aftermarket industry, today announced record revenue and earnings for its fourth quarter and full-year ended Dec...
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenes...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.